Navigation Links
Steve Jobs' Death Highlights Critical Need for New Therapies for Pancreatic Cancer
Date:10/10/2011

WHITE PLAINS, N.Y., Oct. 10, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) joins in grieving the untimely death of Apple Co-Founder Steve Jobs from pancreatic cancer. Jobs' death comes on the heels of other high profile deaths from the disease - those of Nobel Laureate Ralph Steinman last week, and actor Patrick Swayze two years ago.

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

These deaths bring to light a disease with an extremely poor prognosis for which there are limited therapies. The five-year relative survival rate for this patient population is less than five percent.

But better news may come in the form of therapies originally approved to treat patients with blood cancers. Roughly 50 percent of the cancer drugs approved by the Food & Drug Administration (FDA) in the past decade were first approved to treat patients with a form of blood cancer. Many of these drugs are now commonly used to help additional patients and some are showing promise against certain solid tumors, including pancreatic cancer.

LLS helped advance Revlimid®, a drug that can enhance anti-cancer immune responses and block cancer-feeding blood supplies. It is FDA-approved for patients diagnosed with myeloma or myelodysplastic syndromes.  Based on exciting laboratory results, Revlimid is now being tested with a standard chemotherapy in clinical trials for pancreatic cancer patients.

Likewise, LLS funded research advanced Zolinza®, a first-in-class enzyme-targeting drug that can kill cancer cells by reprogramming critical gene activities. Zolinza is FDA-approved to treat certain lymphoma patients, and being tested in clinical trials for pancreatic cancer patients.

"The passing of the visionary Steve Jobs was a truly sad occasion and his death has brought attention to a deadly cancer for which there are very limited opt
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stevens researchers pioneer novel technique to make plasmonic nanogap arrays
2. ONR funds study of nanoscale wetting dynamics of superhydrophobic surfaces at Stevens
3. Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way"
4. Dr. Frank Fisher of Stevens selected for Fulbright specialist roster
5. Steven Seagal Asks For Russian PM Vladimir Putins Support in Immortality Research
6. Dr. Stefan Strauf of physics at Stevens receives NSF CAREER Award for quantum research
7. Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011
8. Nanoimprint lithography NSF grant awarded to micro device lab at Stevens
9. Microfluidic devices advance 3-D tissue engineering at Stevens
10. Xiaoguang Meng receives honorary master of engineering from Stevens
11. AMTs EGM Passes All Resolutions and Strengthens Supervisory Board With Joseph Feczko, Steven Holtzman and Francois Meyer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... the Deerfield Healthcare Innovations Fund, L.P., which will invest ... therapeutic interventions in genetic diseases, cancer, and orphan diseases. ... that can transform how therapeutics are developed and improve ... The fund, one of the largest healthcare-focused venture funds ...
(Date:7/28/2015)... July 28, 2015  Kerastem Technologies announce that the ... U.S. FDA Center For Biologics Evaluation and Research (CBER) ... a clinical trial investigating the safety and feasibility of ... early male pattern baldness (androgenic alopecia). The ... initial clinical work in Europe ...
(Date:7/28/2015)... , July 28, 2015 BioStructures, ... it has hit a milestone of 4,000 implantations ... FDA 510(k) cleared in early 2014 as a ... posterolateral spine fusion procedures.  This is a distinguished ... less than 6% of new synthetic products have ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that it has granted to German life sciences ... development and commercialization of biotechnology (collectively, the "Optionee"), ... oral allogenic tumor vaccine technology (the "Technology"), including ... cancer which is ready to enter a Phase ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Revolutionary Bone Graft Exceeds Expectations 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3
... DIEGO, May 1, 2012 AnaptysBio, Inc., a ... discovery partnership with Gilead Sciences, Inc. to develop ... http://photos.prnewswire.com/prnh/20111205/SF16052LOGO ) Under this partnership, ... platform will be transferred to Gilead for worldwide ...
... research project, funded by the British Heart Foundation (BHF), has ... doctors predict a patient,s risk of having a heart attack ... BHF Centre of Research Excellence, in collaboration with the University ... combining PET and CT scanning to image the disease processes ...
... age of high-speed computing, the photon is king. However, producing ... time-consuming process, until now. Thanks to the work by ... The Edward S. Rogers Sr. Department of Electrical & Computer ... the production of special class of photons faster and easier. ...
Cached Biology Technology:AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences 2 Scientists develop new technique that could improve heart attack prediction 2Research breakthrough takes supercomputing out of the lab 2
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... high tech tools, researchers have identified three proteins that ... 20 months before the rejection occurred. , Lung transplant ... about 45% over five years, said lead investigator and ... to predict which transplants will fail, and when signs ...
... for the survival of many types of cells stimulates ... that connect the cerebral cortex with the spinal cord ... lateral sclerosis (ALS or Lou Gehrig's disease). In ... from Massachusetts General Hospital (MGH) and the Harvard Stem ...
... during the earliest phases of infection appears to depend ... called HLA Class I that have been inherited, as ... molecules display to the T lymphocytes that usually destroy ... issue of PLOS Medicine, researchers from the Partners AIDS ...
Cached Biology News:Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3Growth factor stimulates rapid extension of key motor neurons in brain 2Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
Request Info...
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Biology Products: